FWP - Forward Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.9350
-0.0150 (-1.58%)
As of 1:29PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9500
Open1.0000
Bid0.9400 x 1300
Ask1.0000 x 3200
Day's Range0.9350 - 1.0000
52 Week Range0.7100 - 3.6500
Volume307
Avg. Volume10,337
Market Cap44.447M
Beta (3Y Monthly)3.64
PE Ratio (TTM)N/A
EPS (TTM)-0.1840
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-09-12
1y Target Est37.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018

    Forward Pharma A/S (FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. During the year ended December 31, 2017, we recognized as revenue the $1.25 billion nonrecurring non-refundable fee (“Non-refundable Fee”) that was received during February 2017 in connection with the Settlement and License Agreement (“License Agreement”) entered into with two wholly owned subsidiaries of Biogen, Inc. (collectively, “Biogen”).

  • GlobeNewswire2 months ago

    Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference

    Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.

  • Reuters7 months ago

    Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

    The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.

  • Benzinga8 months ago

    The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...